BioNTech SE (BVMF:B1NT34)

Brazil flag Brazil · Delayed Price · Currency is BRL
35.16
-0.36 (-1.01%)
At close: Feb 27, 2026
Market Cap141.93B -8.3%
Revenue (ttm)19.71B +3.7%
Net Income-3.57B
EPS-14.91
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume110
Average Volume473
Open35.08
Previous Close35.52
Day's Range35.08 - 35.20
52-Week Range30.80 - 43.61
Beta1.51
RSI46.99
Earnings DateMar 10, 2026

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6,772
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1NT34
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements